Literature DB >> 26002847

Reply to Harrington et al.

Sreetha Sidharthan1, Anita Kohli1, Shyam Kottilil2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26002847      PMCID： PMC4542601          DOI： 10.1093/cid/civ403

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.

Authors:  Patrick R Harrington; Damon J Deming; Takashi E Komatsu; Lisa K Naeger
Journal:  Clin Infect Dis       Date:  2015-05-22       Impact factor: 9.079

2.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

3.  Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Ira M Jacobson; Gregory J Dore; Graham R Foster; Michael W Fried; Monica Radu; Vladimir V Rafalsky; Larysa Moroz; Antonio Craxi; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Jane Scott; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Lancet       Date:  2014-06-04       Impact factor: 79.321

4.  Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

Authors:  Sreetha Sidharthan; Anita Kohli; Zayani Sims; Amy Nelson; Anu Osinusi; Henry Masur; Shyam Kottilil
Journal:  Clin Infect Dis       Date:  2015-03-02       Impact factor: 9.079

5.  Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Authors:  Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Michael Gschwantler; Andreas Maieron; Harald Brunner; Rudolf Stauber; Martin Bischof; Bernhard Bauer; Christian Datz; Karin Löschenberger; Elisabeth Formann; Katharina Staufer; Petra Steindl-Munda
Journal:  Gastroenterology       Date:  2008-05-27       Impact factor: 22.682
  5 in total
  1 in total

1.  Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.

Authors:  Miguel Malespin; Tamara Benyashvili; Susan L Uprichard; Alan S Perelson; Harel Dahari; Scott J Cotler
Journal:  Therap Adv Gastroenterol       Date:  2016-10-17       Impact factor: 4.409
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.